FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099079381> ?p ?o ?g. }

• W2099079381 endingPage "875" @default.
• W2099079381 startingPage "862" @default.
• W2099079381 abstract "Increasing the efficacy of chemotherapeutics by reducing chemoresistance may be a useful strategy in cancer therapy. Constitutive activation of nuclear factor-kappa B (NF-kappaB) is a hallmark of various cancers, including melanoma, which is almost universally resistant to chemotherapy. NF-kappaB is regulated by inhibitory kappaB (IkappaB) proteins, which are in turn phosphorylated by the IkappaB kinase (IKK) complex.The effect on NF-kappaB activity of a novel small-molecule inhibitor of the beta subunit of IKK (KINK-1; kinase inhibitor of nuclear factor-kappaB-1) was assessed by measuring phosphorylation of the alpha subunit of IkappaB by immunoblotting, DNA binding by electrophoretic mobility shift assays, and nuclear translocation of NF-kappaB using immunofluorescence. Regulation of NF-kappaB-dependent gene expression was determined by microarray analysis, real-time and semiquantitative reverse transcription polymerase chain reaction (RT-PCR), and Western blot analyses. The effects of KINK-1 (alone and in combination with cytostatic agents) on melanoma cells were characterized by assessing proliferation, soft agar colony formation, and markers of apoptosis. The antitumoral efficacy of KINK-1 in combination with the cytostatic agents doxorubicin or camptothecin (all injected intraperitoneally) was tested in vivo by measuring lung weight and counting metastases in C57BL6 mice (groups of six) bearing metastases of melanoma cells. All statistical tests were two-sided. Results KINK-1 strongly suppressed both constitutive and induced NF-kappaB activity in melanoma cells. It reduced the expression of NF-kappaB-dependent gene products that regulate proliferation, cytokine production, and antiapoptotic responses but exhibited little antiproliferative or proapoptotic activity at the cellular level. However, KINK-1 markedly increased the activities of some cytostatic agents in vitro and abrogated doxorubicin-induced NF-kappaB activation. Combined treatment of C57BL6 mice that had been injected with melanoma cells with KINK-1 and doxorubicin or camptothecin reduced metastases and pulmonary tumor mass compared with either treatment alone (mean lung weight 19 days after injection of melanoma cells of mice treated with 3 mg/kg KINK-1 alone, 1 mg/kg doxorubicin alone, and 1 mg/kg doxorubicin plus 3 mg/kg KINK-1 = 260 mg, 95% confidence interval (CI) = 216 to 305 mg; 268 mg, 95% CI = 224 to 313 mg; and 181 mg, 95% CI = 171 to 192 mg, respectively, P < .001 from t tests comparing mean lung weight of double-treated mice to that in mice treated with either compound alone).Inhibition of constitutive and induced IKKbeta-activity through treatment with KINK-1 might increase tumor susceptibility to chemotherapy." @default.
• W2099079381 created "2016-06-24" @default.
• W2099079381 creator A5009377549 @default.
• W2099079381 creator A5024606160 @default.
• W2099079381 creator A5051451842 @default.
• W2099079381 creator A5052127632 @default.
• W2099079381 creator A5061847107 @default.
• W2099079381 creator A5065745386 @default.
• W2099079381 creator A5068472134 @default.
• W2099079381 creator A5089977110 @default.
• W2099079381 creator A5091590103 @default.
• W2099079381 creator A5091904035 @default.
• W2099079381 date "2008-06-18" @default.
• W2099079381 modified "2023-10-13" @default.
• W2099079381 title "KINK-1, a Novel Small-Molecule Inhibitor of IKKβ, and the Susceptibility of Melanoma Cells to Antitumoral Treatment" @default.
• W2099079381 cites W1499747652 @default.
• W2099079381 cites W1548219170 @default.
• W2099079381 cites W1580870868 @default.
• W2099079381 cites W1812064661 @default.
• W2099079381 cites W1881072801 @default.
• W2099079381 cites W1881147845 @default.
• W2099079381 cites W1896839509 @default.
• W2099079381 cites W1968730445 @default.
• W2099079381 cites W1970262077 @default.
• W2099079381 cites W1976382352 @default.
• W2099079381 cites W1982530463 @default.
• W2099079381 cites W1992841021 @default.
• W2099079381 cites W1993941415 @default.
• W2099079381 cites W1999184204 @default.
• W2099079381 cites W2001307433 @default.
• W2099079381 cites W2001580102 @default.
• W2099079381 cites W2004121432 @default.
• W2099079381 cites W2004979714 @default.
• W2099079381 cites W2005339886 @default.
• W2099079381 cites W2007456673 @default.
• W2099079381 cites W2010183849 @default.
• W2099079381 cites W2034031966 @default.
• W2099079381 cites W2034749827 @default.
• W2099079381 cites W2035728486 @default.
• W2099079381 cites W2043892945 @default.
• W2099079381 cites W2046056065 @default.
• W2099079381 cites W2047549551 @default.
• W2099079381 cites W2050458717 @default.
• W2099079381 cites W2052908553 @default.
• W2099079381 cites W2055080743 @default.
• W2099079381 cites W2055791127 @default.
• W2099079381 cites W2056407781 @default.
• W2099079381 cites W2061552614 @default.
• W2099079381 cites W2066606648 @default.
• W2099079381 cites W2067465277 @default.
• W2099079381 cites W2070703301 @default.
• W2099079381 cites W2081367726 @default.
• W2099079381 cites W2083213572 @default.
• W2099079381 cites W2087973500 @default.
• W2099079381 cites W2091407868 @default.
• W2099079381 cites W2093944970 @default.
• W2099079381 cites W2095354110 @default.
• W2099079381 cites W2097521347 @default.
• W2099079381 cites W2100382285 @default.
• W2099079381 cites W2118315567 @default.
• W2099079381 cites W2121411068 @default.
• W2099079381 cites W2121937165 @default.
• W2099079381 cites W2122598723 @default.
• W2099079381 cites W2124076790 @default.
• W2099079381 cites W2127474966 @default.
• W2099079381 cites W2130542755 @default.
• W2099079381 cites W2137016259 @default.
• W2099079381 cites W2145028653 @default.
• W2099079381 cites W2151015976 @default.
• W2099079381 cites W2151837372 @default.
• W2099079381 cites W2152315800 @default.
• W2099079381 cites W2169724245 @default.
• W2099079381 cites W2315613727 @default.
• W2099079381 cites W2316716290 @default.
• W2099079381 cites W2470223656 @default.
• W2099079381 cites W2999065750 @default.
• W2099079381 cites W39614084 @default.
• W2099079381 cites W4211042579 @default.
• W2099079381 cites W4379365691 @default.
• W2099079381 cites W81987094 @default.
• W2099079381 doi "https://doi.org/10.1093/jnci/djn174" @default.
• W2099079381 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18544741" @default.
• W2099079381 hasPublicationYear "2008" @default.
• W2099079381 type Work @default.
• W2099079381 sameAs 2099079381 @default.
• W2099079381 citedByCount "56" @default.
• W2099079381 countsByYear W20990793812012 @default.
• W2099079381 countsByYear W20990793812013 @default.
• W2099079381 countsByYear W20990793812014 @default.
• W2099079381 countsByYear W20990793812015 @default.
• W2099079381 countsByYear W20990793812016 @default.
• W2099079381 countsByYear W20990793812017 @default.
• W2099079381 countsByYear W20990793812018 @default.
• W2099079381 countsByYear W20990793812020 @default.
• W2099079381 countsByYear W20990793812021 @default.
• W2099079381 countsByYear W20990793812022 @default.
• W2099079381 countsByYear W20990793812023 @default.
• W2099079381 crossrefType "journal-article" @default.

• next